Risk of angiotensin converting enzyme inhibitor intolerance in asthma compared to the general population

Study identification

• EU PAS number:
  EUPAS33586
• Study ID:
  33587
• Official title and acronym:
  Risk of angiotensin converting enzyme inhibitor intolerance in asthma compared to the general population
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  This study will examine the risk of intolerance to angiotensin converting enzyme (ACE) inhibitors in asthma compared to the general population. Intolerance will be defined by switching to an angiotensin-II receptor blocker after initiation of ACE inhibitor therapy.
• Study status:
  Ongoing

Research institutions and networks

Institutions

University of Dundee

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 11/07/2016

Actual: 11/07/2016

Study start date

Planned: 18/07/2016

Actual: 18/07/2016

Data analysis start date

Planned: 10/04/2017

Actual: 10/04/2017

Date of final study report

Planned: 24/02/2020

Sources of funding

Non-for-profit organisation (e.g. charity)

Other

More details on funding

Tenovus Scotland, Internal University of Dundee resources

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable